Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 546 results found since Jan 2013.
Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
Benefit of thrombolytic therapy in patients with acute stroke, who are on anticoagulant treatment, is not well addressed. The aim of this study was to investigate whether apixaban can modify the thrombolytic efficacy of alteplase in vitro. Static and flow models and two variants of red blood cell (RBC) dominant clots, with and without apixaban, were used. Clots were prepared from the blood of healthy human donors and subsequently exposed to alteplase treatment. Apixaban and alteplase were used in clinically relevant concentrations. Clot lysis in the static model was determined both by clot weight and spectrophotometric det...
Source: Frontiers in Pharmacology - September 15, 2021 Category: Drugs & Pharmacology Source Type: research
Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210902152539. Online ahead of print.ABSTRACTVenous thromboembolism clinically presents as deep venous thrombosis or acute pulmonary embolism and is globally recognized as the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Although pulmonary embolism does not typically cause severe pulmonary hypertension in the acute setting, thrombus organization and fibrosis can lead to stenosis or obliteration of pulmonary arteries in a minority of patients, which in turn result in severe pulmonary hypertension and right heart failure. This d...
Source: Current Pharmaceutical Design - September 3, 2021 Category: Drugs & Pharmacology Authors: Nikolaos Papakonstantinou Polydoros Kampaktsis Filippos-Paschalis Rorris Ilias Doulamis Aspasia Tzani Sotirios Katsaridis Dimitrios Avgerinos Source Type: research
Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research
